GLPwatch
Sarcopenia / muscle loss
41 FAERS reports across 1 drug
Last updated 2026-05-28 15:46 UTCSarcopenia is the gradual loss of muscle mass and strength that happens naturally as people age.
Plain-language definition of the term.
Some studies suggest GLP-1 drugs like liraglutide and semaglutide may influence muscle loss or sarcopenia through pathways such as SIRT1, YAP-TAZ, or by inhibiting atrophy-related genes, while one retrospective cohort study reports an association between semaglutide and accelerated sarcopenia in older adults with type 2 diabetes.
AI summary of the sources below.
FAERS report counts (as of 2026Q1) reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
| Drug | FAERS reports | Quarter |
|---|---|---|
| Rybelsus | 41 | 2026Q1 |
Research mentioning sarcopenia / muscle loss (9)
- Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.
- GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway.
- Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents.
- Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice.
- Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.
- Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy.
- Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway.
- Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.
- Glucagon-like peptide-1 receptor (GLP-1R) agonists prevent tributyltin-induced muscle atrophy/wasting via restoring GLP-1R signaling in vitro and in mice.